5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial-Reference-Cited by-同舟云学术

5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial

Published:2020-06 Issue:6 Volume:2 Page:e339-e346
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Marzo-Ortega Helena,Sieper Joachim,Kivitz Alan J,Blanco Ricardo,Cohen Martin,Pavelka Karel,Delicha Eumorphia M,Stefanska Anna,Richards Hanno B,Rohrer Susanne

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference24 articles.

1. Ankylosing spondylitis;Braun;Lancet,2007

2. Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbance;Aissaoui;Rheumatol Int,2012

3. Fatigue in ankylosing spondylitis—why is it ignored?;Calin;J Rheumatol,1993

4. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors;Jones;J Rheumatol,1996

5. Prognosis, course of disease, and treatment of the spondyloarthropathies;Leirisalo-Repo;Rheum Dis Clin North Am,1998

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis;Frontiers in Immunology;2024-07-15

2. The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis;Immunotherapy;2024-03-21

3. Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process;Rheumatology and Therapy;2023-07-14

4. Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA);RMD Open;2023-03

5. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network;The Journal of Rheumatology;2023-01-15